Maxim Group Maintains Buy on AIM ImmunoTech, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Jason McCarthy maintains a Buy rating on AIM ImmunoTech but lowers the price target from $2 to $1.
October 22, 2024 | 9:29 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Maxim Group's analyst Jason McCarthy continues to recommend buying AIM ImmunoTech but has reduced the price target from $2 to $1, indicating a more cautious outlook.
The Buy rating suggests continued confidence in AIM ImmunoTech's potential, but the lowered price target reflects a more conservative valuation, possibly due to market conditions or company performance. This mixed signal may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100